Texas is currently home to 4891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation
Recruiting
To look at the effect of a recipient's ancestry and socio-economic status on their choice of bone marrow transplantation donor cells and their chance of receiving genetically similar (allogeneic) bone marrow cells versus cells that are not genetically similar (allograft).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Allogeneic Transplantation
Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women
Recruiting
To learn more about women's attitudes toward and knowledge about endometrial cancer and options that might decrease the risk of developing
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Endometrial Cancer
A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)
Recruiting
To find out if local consolidation therapy (such as radiation therapy with or without other local therapies such as surgery, ablation \[the removal or destruction of a body part or tissue or its function\], or embolization \[a procedure that uses particles, such as tiny gelatin sponges or beads, to block a blood vessel\]) to all progressive sites of disease can help to control the disease compared with next-line systemic therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: OligoProgressive Metastatic Disease
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Recruiting
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Research Site, Fort Worth, Texas
Conditions: Non-Small Cell Lung Cancer
Prospective Evaluation of the Relation Between Different Questionnaires Measuring Radiation-induced Side-effect
Recruiting
To learn more about how you would rate the intensity or severity of your symptoms during or after radiation therapy using questionnaires with different rating scales.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Radiation
Phase I Study of HC-7366 for Acute Myeloid Leukemia
Recruiting
To find a recommended dose of HC-7366 to patients with AML. The safety and effects of this drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
Recruiting
To learn if the combination of axicabtagene ciloleucel (axi-cel) and glofitamab as first-line therapy in high-risk LBCL participants or as second-line therapy in LBCL participants can help to control the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: B Cell Lymphoma
Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis
Recruiting
To follow up with all our participants with juvenile-onset mycosis fungoides, check on their status, and ask them or their parents about long term outcomes associated with their condition.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphomatoid Papulosis, Mycosis Fungoides
Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE)
Recruiting
The FRACTURE Trial is a prospective, non-randomized, single-arm, multicenter, interventional study in US and international centers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Methodist Healthcare Methodist Research Institute, San Antonio, Texas
Conditions: Coronary Artery Disease, Coronary Artery Calcification
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
Recruiting
To learn if regorafenib can help to control the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Gastrointestinal Stromal Tumors
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
Recruiting
To learn about the safety and effects of a drug called REGN5678 when it is given to patients with high-risk prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Prostate Cancer, Radical Prostatectomy
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
Recruiting
To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Myeloma